VEGFA and macular retinal edema: Anti-vascular endothelial growth factor (VEGF) is the mainstay of treatment for patients with macular oedema secondary to CRVO, however, the incidental effect of this treatment on the natural history of retinal nonperfusion is unclear, largely because the treatment regimen, initial loading frequency, and drug type are determined by the CMO, investigator preference and cost rather than retinal perfusion.